Rosen Law Firm reminded purchasers of ARS Pharmaceuticals, Inc. securities traded on Nasdaq under the ticker SPRY about an October 5, 2026 deadline to seek appointment as lead plaintiff in a securities class action. The proposed Class Period covers purchases made from March 9, 2026, through June 24, 2026, inclusive. The lawsuit alleges that ARS Pharmaceuticals and other defendants gave investors overly positive information about the expected timing of expanded CVS Caremark insurance coverage for neffy, the company's epinephrine nasal spray. The complaint claims defendants expressed confidence that coverage would begin on July 1, 2026, and be available for the summer and back-to-school allergy seasons while allegedly concealing or misrepresenting adverse facts about the timeline. Investors allegedly bought securities at artificially inflated prices and suffered losses when the purported truth entered the market. A class action lawsuit has been filed, but no class has been certified. Investors may contact Rosen without paying upfront fees or costs under a contingency fee arrangement, retain counsel of their choice, remain absent class members or take no action. Participation in any potential recovery does not depend on serving as lead plaintiff.